 | |
| Company type | Private limited company |
|---|---|
| Founded | 1982 |
| Founder | Peter FitzGerald |
| Headquarters | Crumlin, County Antrim, Northern Ireland, UK |
Number of locations | 145 countries |
Key people | Peter FitzGerald (owner) |
| Revenue |  £619,000,000 (2021)[1] |
| £275,000,000 (2021)[1] | |
| Total assets |  £47,700,000 (2018) |
| Website | www |
Randox is a Northern Irish health and toxicology company in the in vitro diagnostics industry headquartered in Crumlin, County Antrim, Northern Ireland, owned by Peter FitzGerald. The company develops diagnostic solutions for hospitals, clinical, research and molecular labs, food testing, forensic toxicology, veterinary labs and life sciences. It develops, manufactures and markets reagents and equipment for laboratory medicine, with a distribution network of 145 countries. Randox is the biggest polymerase chain reaction testing provider in the United Kingdom and Republic of Ireland.[2][3][4] Randox received three contracts by the Department of Health and Social Care without having to compete for a tender.
In 2020, Randox was awarded nearly £500 million by the government of the United Kingdom to provide private-sector COVID-19 testing at the cost of about £49 per kit.[5]
- ^ a b Cite error: The named reference
tylerwas invoked but never defined (see the help page). - ^ 18 March 2011 – Foster announces 242 new jobs at Randox Laboratories | Northern Ireland Executive. Northernireland.gov.uk (18 March 2011).
- ^ Proteome Sciences Licenses Stroke Biomarkers to Randox Archived 26 January 2013 at archive.today. IVD Technology (5 April 2012).
- ^ "Randox launches COVID-19 testing lab at Heathrow Airport". 27 January 2021.
- ^ Garside, Juliette; Smith, Joseph (4 November 2020). "Tory-linked firm involved in testing failure given new £347m Covid contract". The Guardian. London.